Pazufloxacin opthalmic - Laboratorios Sophia
Alternative Names: PRO-157; Project-157Latest Information Update: 07 Dec 2022
At a glance
- Originator Laboratorios Sophia
- Class Anti-infectives; Antibacterials; Fluoroquinolones; Oxazines; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial conjunctivitis
Most Recent Events
- 07 Dec 2022 No development reported - Phase-II for Bacterial conjunctivitis (In adolescents, In children, In the elderly, In infants, In neonates, In adults) in Mexico (Ophthalmic) prior to December 2022 (NCT02980523)
- 07 Dec 2022 No development reported - Phase-III for Bacterial conjunctivitis (In adolescents, In children, In the elderly, In adults) in Mexico (Ophthalmic) prior to December 2022 (NCT03696342)
- 24 Mar 2020 Laboratorios Sophia terminates a phase III trial in Bacterial conjunctivitis (In children, In the elderly, In adolescents, In adults) in Mexico (Ophthalmic) due to sponsor's convenience (NCT03696342)